Tedizolid Phosphate Suppliers & Bulk Manufacturers
Available Forms: Tablet / Injection
Available Strengths: 200 mg
Reference Brands: Sivextro (USA)
Category:
Antibiotics
Tedizolid Phosphate is available in Tablet / Injection
and strengths such as 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tedizolid Phosphate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tedizolid Phosphate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tedizolid, marketed under the brand name Sivextro by Merck, is a next-generation oxazolidinone-class antibiotic used for the treatment of acute bacterial skin and skin structure infections (ABSSSI), also referred to as complicated skin and skin-structure infections (cSSSIs). Tedizolid phosphate is a phosphate ester prodrug that is converted in the body to the active compound, tedizolid, which exerts antibacterial effects.
Developed originally by Cubist Pharmaceuticals following the acquisition of Trius Therapeutics and based on the original research by Dong-A Pharmaceuticals, Tedizolid offers enhanced potency against Gram-positive pathogens, including Staphylococcus aureus and Streptococcus species. It works by binding to the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis and preventing bacterial growth.
Tedizolid phosphate is available in both oral and intravenous formulations at 200 mg strength, allowing for flexible dosing in clinical settings. The medication is typically administered once daily for a six-day course, providing effective treatment with a favorable safety profile. Its targeted mechanism and convenient dosing make it a valuable option for managing serious skin infections caused by susceptible bacteria.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing